Parkinson’s disease induced pluripotent stem cells with triplication of the α-synuclein locus
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
A major barrier to research on Parkinson's disease is inaccessibility of diseased tissue for study. One solution is to derive induced pluripotent stem cells from patients and differentiate them into neurons affected by disease. Triplication of SNCA, encoding α-synuclein, causes a fully penetrant, aggressive form of Parkinson's disease with dementia. α-Synuclein dysfunction is the critical pathogenic event in Parkinson's disease, multiple system atrophy and dementia with Lewy bodies. Here we produce multiple induced pluripotent stem cell lines from an SNCA triplication patient and an unaffected first-degree relative. When these cells are differentiated into midbrain dopaminergic neurons, those from the patient produce double the amount of α-synuclein protein as neurons from the unaffected relative, precisely recapitulating the cause of Parkinson's disease in these individuals. This model represents a new experimental system to identify compounds that reduce levels of α-synuclein, and to investigate the mechanistic basis of neurodegeneration caused by α-synuclein dysfunction. Pluripotent stem cells can be generated from the somatic cells of humans and are a useful model to study disease. Here, pluripotent stem cells are made from a patient with familial Parkinson's disease, and the resulting neurons exhibit elevated levels of α-synuclein, recapitulating the molecular features of the patient's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“SNCA triplication patient iPSC-derived dopaminergic neurons showed α-synuclein protein over accumulation which was consistent with pathological phenotype in PD patient [35].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Efficient Derivation of Functional Floor Plate Tissue from Human Embryonic Stem Cells
Fasano, C. A., Chambers, S. M., Lee, G., Tomishima, M. J., & Studer, L. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.03.001 · Cited by 209 · cited 1×
“The dual SMAD inhibition protocol has been employed to generate floor plate tissue from human ESC”
MethodRetractedSubramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673 · cited 1×
“A potential solution is to utilize reprogamming technology to generate disease-specific induced pluripotent stem cells (iPSCs”
BackgroundAnalyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190 · cited 1×
“Results were normalized to human TBP using the comparative C(T) metho”
MethodSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Self-citationHighly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling
Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M., & Studer, L. (2009) · Nature Biotechnology · doi:10.1038/nbt.1529 · Cited by 3,620 · cited 1×
“Directed differentiation to dopaminergic neurons We used a feeder-free monolayer culture method of inducing neural differentiation under defined conditions, via dual inhibition of SMAD signallin”
Method
Cited by
Items 201–300 of 484
Targeting the inflammasome in Parkinson’s disease
Su, Q., Ng, W. L., Goh, S. Y., Gulam, M. Y., Wang, L., Tan, E., Ahn, M., & Chao, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.957705 · Cited by 34
“In addition, the clonal heterogeneity of the iPSC derived from the same donor makes it difficult to define meaningful phenotypic differences (Devine et al., 2011).”
BackgroundPrediction of mechanistic subtypes of Parkinson’s using patient-derived stem cell models
D’Sa, K., Evans, J. R., Virdi, G. S., Vecchi, G., Adam, A., Bertolli, O., Fleming, J., Chang, H., Leighton, C., Horrocks, M. H., et al. (2023) · Nature Machine Intelligence · doi:10.1038/s42256-023-00702-9 · Cited by 36
“…two healthy donors (one generated in house, and one commercial line; Thermo Fisher Scientific) or PD patients carrying mutations (SNCA ×3) who had given signed informed consent for the derivation of hiPSC lines from skin biopsy as part of the European Union IMI-funded program Stem-BANCC 37,38 .”
BackgroundChang, C.-Y., Ting, H.-C., Liu, C.-A., Su, H.-L., Chiou, T., Harn, H., & Lin, S. (2018) · Cell Transplantation · doi:10.1177/0963689718775406 · Cited by 33
Induced Pluripotent Stem Cells: Progress toward Clinical Translation from Bench to Bedside
Fakoya, A. O. J., Omole, A. E., Satyadev, N., & Haider, K. H. (2022) · Springer eBooks · doi:10.1007/978-981-16-6016-0_40-1 · Cited by 29
Modeling Cell-Cell Interactions in Parkinson’s Disease Using Human Stem Cell-Based Models
Simmnacher, K., Lanfer, J., Rizo, T., Kaindl, J., & Winner, B. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00571 · Cited by 35
Kouroupi, G., Antoniou, N., Prodromidou, K., Taoufik, E., & Matsas, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197113 · Cited by 32
MacDougall, G., Brown, L. Y., Kantor, B., & Chiba‐Falek, O. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.01.001 · Cited by 33
Chrysanthou, M., Estruch, I. M., Rietjens, I. M. C. M., Wichers, H. J., & Hoppenbrouwers, T. (2022) · Nutrients · doi:10.3390/nu14020363 · Cited by 34
Czuppa, M., Dhingra, A., Zhou, Q., Schludi, C., König, L. E., Scharf, E., Farny, D., Dalmia, A., Täger, J., Castillo-Lizardo, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110913 · Cited by 29
Sato, M., Takizawa, H., Nakamura, A., Turner, B. J., Shabanpoor, F., & Aoki, Y. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00297 · Cited by 32
“, 2012), Huntington’s (Kaye and Finkbeiner, 2013), Parkinson’s disease (PD; Devine et al., 2011), and Alzheimer’s disease (AD; Ooi et al.”
Trevisan, M., Sinigaglia, A., Desole, G., Berto, A., Pacenti, M., Palù, G., & Barzon, L. (2015) · Viruses · doi:10.3390/v7072800 · Cited by 28
“Likewise, in vitro models of monogenic and multi-factorial neurological and metabolic diseases have been set up using patient-specific iPSC-derived cells [31–37].”
Iannielli, A., Luoni, M., Giannelli, S. G., Ferese, R., Ordazzo, G., Fossati, M., Raimondi, A., Opazo, F., Corti, O., Prehn, J. H. M., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05330-6 · Cited by 35
Multifaceted applications of nanomaterials in cell engineering and therapy
Chen, H., Zeng, Y. C., Liu, W., Zhao, S., Wu, J., & Du, Y. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.08.002 · Cited by 30
“In the third example, iPS cell lines from both a Parkinson's disease patient and an unaffected relative were constructed for comparison (Devine et al., 2011).”
Stem cells and the treatment of Parkinson's disease
Ali, F. R., Stott, S., & Barker, R. A. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.12.017 · Cited by 29
“…from the patients produce and accumulate more α-synuclein protein than neurons from the unaffected relatives, and are more vulnerable to oxidative stress induced cell death, again recapitulating some of the in vivo pathology of PD seen in these families (Byers et al., 2011; Devine et al., 2011).”
Guillaud, L., Garanzini, A., Zakhia, S., de la Fuente, S., Dimitrov, D., Boerner, S., & Terenzio, M. (2025) · Science Advances · doi:10.1126/sciadv.adq6077 · Cited by 32
“The PARK2 ( 36 , 83 ) and SNCA ( 84 ) lines used in this study have been well characterized for their mitochondrial dysfunction and SNCA aggregation.”
Wurster, I., Quadalti, C., Rossi, M., Hauser, A., Deuschle, C., Schulte, C., Waniek, K., Lachmann, I., la Fougère, C., Doppler, K., et al. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00379-8 · Cited by 28
Induced Pluripotent Stem Cells to Model and Treat Neurogenetic Disorders
Wang, H., & Doering, L. C. (2012) · Neural Plasticity · doi:10.1155/2012/346053 · Cited by 34
Understanding Parkinson’s Disease through the Use of Cell Reprogramming
Playne, R., & Connor, B. J. (2017) · Stem Cell Reviews and Reports · doi:10.1007/s12015-017-9717-5 · Cited by 32
Cell-specific overexpression of COMT in dopaminergic neurons of Parkinson’s disease
Kuzumaki, N., Suda, Y., Iwasawa, C., Narita, M., Sone, T., Watanabe, M., Maekawa, A., Matsumoto, T., Akamatsu, W., Igarashi, K., et al. (2019) · Brain · doi:10.1093/brain/awz084 · Cited by 26
Lipase regulation of cellular fatty acid homeostasis as a Parkinson’s disease therapeutic strategy
Fanning, S., Cirka, H., Thies, J. L., Jeong, J., Niemi, S. M., Yoon, J. H., Ho, G. P. H., Ávila-Pacheco, J., Dettmer, U., Liu, L., et al. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00335-6 · Cited by 26
Holmqvist, S., Brouwer, M., Djelloul, M., Diaz, A. G., Devine, M. J., Hammarberg, A., Fog, K., Kunath, T., & Roybon, L. (2015) · Stem Cell Research · doi:10.1016/j.scr.2015.05.014 · Cited by 26
“We nucleofected the previously characterized hiPSC line, NAS2 (Devine et al., 2011), and harvested G418-resistant clones (n = 88) which we pre-screened using the methodology we described for the hESC clones.”
MethodSelf-citationLeem, Y., Park, J., Park, J.-E., Kim, D.-Y., Kang, J. L., & Kim, H.-S. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110576 · Cited by 29
Romano, G., Morales, F., Marino, I. R., & Giordano, A. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24437 · Cited by 26
“…applications for the investigation of a wide range of human diseases (Moretti JOURNAL OF CELLULAR PHYSIOLOGY et al., 2010; Rosenzweig, 2010; Devine et al., 2011; Itzhaki et al., 2011; Paşca et al., 2011; Qiang et al., 2011; Tiscornia et al., 2011; Yagi et al., 2011; Israel et al., 2012;…”
BackgroundATG8-dependent LMX1B-autophagy crosstalk shapes human midbrain dopaminergic neuronal resilience
Jiménez-Moreno, N., Kollareddy, M., Stathakos, P., Moss, J. J., Antón, Z., Shoemark, D. K., Sessions, R. B., Witzgall, R., Caldwell, M. A., & Lane, J. D. (2023) · The Journal of Cell Biology · doi:10.1083/jcb.201910133 · Cited by 29
“To confirm their potential as autophagy transcription factors in the human midbrain, we prepared mDANs from the NAS2 (normal α -synuclein) iPSC line (Devine et al., 2011), using a monolayer protocol that generates high numbers of mDANs expressing midbrain dopaminergic markers, including TH, LMX1A,…”
MethodPhenotypic screens for compounds that target the cellular pathologies underlying Parkinson's disease
Tardiff, D. F., & Lindquist, S. L. (2012) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2012.02.003 · Cited by 28
Murtaza, M., Shan, J., Matigian, N., Todorovic, M., Cook, A. L., Ravishankar, S., Dong, L., Neužil, J., Silburn, P. A., Mackay‐Sim, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154544 · Cited by 27
“However, the variability in the reprogramming process, epigenetic status between cell lines and heterogeneity of neural differentiation [26,28] still raises some concerns about the use of reprogramming in the modelling of human diseases with complex aetiology.”
Carta, A. R., Boi, L., Pisanu, A., Palmas, M. F., Carboni, E., & Simone, A. D. (2020) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2020.108685 · Cited by 29
Modeling Neuropsychiatric and Neurodegenerative Diseases With Induced Pluripotent Stem Cells
LaMarca, E. A., Powell, S. K., Akbarian, S., & Brennand, K. (2018) · Frontiers in Pediatrics · doi:10.3389/fped.2018.00082 · Cited by 30
Generation of human midbrain organoids from induced pluripotent stem cells
Mohamed, N., Mathur, M., da Silva, R. V., Thomas, R. A., Lépine, P., Beitel, L. K., Fon, E. A., & Durcan, T. M. (2019) · MNI Open Research · doi:10.12688/mniopenres.12816.1 · Cited by 28
Patikas, N., Ansari, R., & Metzakopian, E. (2023) · Neuroscience Research · doi:10.1016/j.neures.2023.06.001 · Cited by 28
“The PD patient-derived HMOs carry two extra copies of the SNCA locus, a familial early-onset PD mutation (Devine et al., 2011).”
BackgroundXie, Y., & Zhang, R. X. (2014) · Neurological Sciences · doi:10.1007/s10072-014-1989-9 · Cited by 29
Momčilović, O., Sivapatham, R., Oron, T. R., Meyer, M., Mooney, S. D., Rao, M. S., & Zeng, X. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154890 · Cited by 25
Structural variants in SNCA gene and the implication to synucleinopathies
Chiba‐Falek, O. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.01.014 · Cited by 26
Modeling Parkinson's disease with induced pluripotent stem cells harboring α‐synuclein mutations
Dolt, K. S., Hammachi, F., & Kunath, T. (2017) · Brain Pathology · doi:10.1111/bpa.12526 · Cited by 29
“…Control iPSCs Differentiation Phenotypes Soldner et al (44) A53T SNCA iPSCs Isogenic-corrected A53T SNCA iPSCs Midbrain dopaminergic neurons N/A Devine et al (11) Triplication SNCA iPSCs 1st-degree, unaffected relative iPSCs Midbrain dopaminergic neurons Elevated levels of SNCA mRNA, cellular…”
BackgroundSelf-citationHarnessing the Potential of Stem Cells for Disease Modeling: Progress and Promises
Argentati, C., Tortorella, I., Bazzucchi, M., Morena, F., & Martino, S. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10010008 · Cited by 25
“Parkinson’s disease Patient-derived fibroblasts [41,67]”
BackgroundPaulsen, B. D. S., Silveira, M. S., Galina, A., & Rehen, S. K. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.10.009 · Cited by 25
The Progress of Induced Pluripotent Stem Cells as Models of Parkinson’s Disease
Kang, J.-F., Tang, B., & Guo, J. (2016) · Stem Cells International · doi:10.1155/2016/4126214 · Cited by 25
The role of dopamine in the pathogenesis of GBA1-linked Parkinson's disease
Burbulla, L. F., & Krainc, D. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104545 · Cited by 23
Phenotypic screening with primary neurons to identify drug targets for regeneration and degeneration
Cooper, D. J., Zunino, G., Bixby, J. L., & Lemmon, V. (2016) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2016.07.001 · Cited by 26
“Neurodegenerative disorders including AD (Ooi et al., 2013; Israel et al., 2012), PD (Devine et al., 2011), amyotrophic lateral sclerosis (Egawa et al., 2012), and mental disorders such as schizophrenia (Brennand et al., 2011, 2015) have been modeled using iPS cells; patient-derived neural cells…”
BackgroundDrummond, N. J., Dolt, K. S., Canham, M. A., Kilbride, P., Morris, G. J., & Kunath, T. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.578907 · Cited by 24
Self-citationShum, C., Macedo, S. C., Warre-Cornish, K. M., Cocks, G. D., Price, J., & Srivastava, D. P. (2015) · Hormones and Behavior · doi:10.1016/j.yhbeh.2015.06.014 · Cited by 27
“…(B + C) 2011) and autism spectrum disorders (ASD) (Marchetto et al., 2010; Shcheglovitov et al., 2013), as well as neurodegenerative disorders Alzheimer's disease (AD) (Israel et al., 2012), Parkinson's disease (PD) (Devine et al., 2011) and amyotrophic lateral sclerosis (ALS) (Dimos et al., 2008).”
BackgroundInfluentialCellular reprogramming: a new approach to modelling Parkinson's disease
Hartfield, E. M., Fernandes, H. J. R., Vowles, J., Cowley, S. A., & Wade‐Martins, R. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120159 · Cited by 26
Electrically Conductive Injectable Silk/ PEDOT : PSS Hydrogel for Enhanced Neural Network Formation
Borah, R., O'Sullivan, J., Suku, M., Spurling, D., Clarke, D. D., Nicolosi, V., Caldwell, M. A., & Monaghan, M. G. (2024) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.37859 · Cited by 23
Son, S. M., Siddiqi, F. H., López, A., Ansari, R., Tyrkalska, S. D., Park, S. J., Kunath, T., Metzakopian, E., Fleming, A., & Rubinsztein, D. C. (2025) · Neuron · doi:10.1016/j.neuron.2025.03.028 · Cited by 27
Self-citationInstant Neurons: Directed Somatic Cell Reprogramming Models of Central Nervous System Disorders
Liang, Q., Inoue, K., & Abeliovich, A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.10.027 · Cited by 23
Redefining Parkinson’s Disease Research Using Induced Pluripotent Stem Cells
Pu, J., Jiang, H., Zhang, B., & Feng, J. (2012) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-012-0288-1 · Cited by 24
Gennet, N., Tamburini, C., Nan, X., & Li, M. (2016) · Scientific Reports · doi:10.1038/srep32488 · Cited by 24
Pavăl, D., Rad, F., Rusu, R., Niculae, A.-Ş., Colosi, H. A., Dobrescu, I., & Dronca, E. (2017) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2017.15.3.229 · Cited by 25
Advancing Stem Cell Models of Alpha-Synuclein Gene Regulation in Neurodegenerative Disease
Piper, D., Sastre, D., & Schüle, B. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00199 · Cited by 25
“(Reyes et al., 2015) iPSC Source Skin fibroblasts: 1 patient (SNCA triplication), 1 control (mutation negative family member) (Devine et al., 2011) iPSC Reprogramming/Number of clones Retrovirus pMXs-OSKM Gene Editing N/A iPSC Maintenance/Passaging On SNL feeders in hESC media (KO-DMEM, KSR, L-Glu,…”
Mohamed, N., Larroquette, F., Beitel, L. K., Fon, E. A., & Durcan, T. M. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-181515 · Cited by 26
When synthetic biology meets medicine
Feng, Y., Su, C., Mao, G., Sun, B., Cai, Y., Dai, J., & Ma, Y. (2024) · Life Medicine · doi:10.1093/lifemedi/lnae010 · Cited by 22
Vuidel, A., Cousin, L., Weykopf, B., Haupt, S., Hanifehlou, Z., Wiest-Daesslé, N., Segschneider, M., Lee, J., Kwon, Y., Peitz, M., et al. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.09.001 · Cited by 22
Young, W. (2012) · Journal of Stem Cell Research & Therapy · doi:10.4172/2157-7633.s10-010 · Cited by 24
“Parkinson’s disease, familial LRRK2, SNCA or PINK1 iPSC dopaminergic neurons show impaired mitochondrial function; iPSC dopaminergic neurons have increased expression of key oxidative stress response genes and α-synuclein protein, and increased sensitivity to oxidative-stress; accumulation of autophagic vacuoles [156,…”
BackgroundGao, A., Peng, Y., Deng, Y., & Qing, H. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.076 · Cited by 24
Koh, Y. H., Tan, L. Y., & Ng, S. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00413 · Cited by 20
“…by LDN-193189 and SB431542), early high-dose Sonic Hedgehog (SHH) pathway agonists (such as Purmorphamine or recombinant SHH) and partial glycogen synthase kinase (GSK) inhibitors/Wnt activation (by CHIR99021) (Cooper et al., 2010; Devine et al., 2011; Kriks et al., 2011; Kirkeby et al., 2012).”
BackgroundCell reprogramming therapy for Parkinson’s disease
Dong, W., Liu, S., Li, S., & Wang, Z. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.390965 · Cited by 22
“Previous studies have also shown that iPSC-derived cells from PD patients are more vulnerable in the pathological environment (Devine et al., 2011; Beevers et al., 2013; Sanders et al., 2014; Rakovic et al., 2015; Chung et al., 2016; Bieri et al., 2019; Zambon et al., 2019).”
ResultGrow, D. A., Simmons, D. V., Gómez, J. A., Wanat, M. J., McCarrey, J. R., Paladini, C. A., & Navara, C. S. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0073 · Cited by 21
Parkinson’s disease: what the model systems have taught us so far
Ghatak, S., Trudler, D., Dolatabadi, N., & Ambasudhan, R. (2018) · Journal of Genetics · doi:10.1007/s12041-018-0960-6 · Cited by 23
Induced Pluripotent Stem Cells and Their Use in Cardiac and Neural Regenerative Medicine
Skalová, Š., Švadláková, T., Qureshi, W. M. S., Dev, K., & Mokrý, J. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16024043 · Cited by 21
“Triplication of SNCA causes a fully penetrant, aggressive form of Parkinson’s disease with dementia because of α-synuclein dysfunction [124].”
BackgroundProgress on stem cell research towards the treatment of Parkinson's disease
Gibson, S. A., Gao, G., McDonagh, K., & Shen, S. (2012) · Stem Cell Research & Therapy · doi:10.1186/scrt102 · Cited by 24
Spitalieri, P., Talarico, R. V., Botta, A., Murdocca, M., D’Apice, M. R., Orlandi, A., Giardina, E., Santoro, M., Brancati, F., Novelli, G., et al. (2015) · Cellular Reprogramming · doi:10.1089/cell.2015.0003 · Cited by 19
Cell replacement therapy is the remedial solution for treating Parkinson’s disease
Dhivya, V., & Vellingiri, B. (2017) · Stem Cell Investigation · doi:10.21037/sci.2017.06.08 · Cited by 19
Antonov, S. A., & Novosadova, E. V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073381 · Cited by 24
“SNCA Gene triplication Devine [149], Byers [150], Flierl [151]”
BackgroundParkinson’s disease research: adopting a more human perspective to accelerate advances
Marshall, L. J., & Willett, C. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.010 · Cited by 19
The promises of stem cells: stem cell therapy for movement disorders
Mochizuki, H., Choong, C., & Yasuda, T. (2013) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(13)70031-2 · Cited by 18
“iPSC-derived midbrain dopaminergic neurons from a patient with a triplication in the a-synuclein gene (SNCA) showed accumulation of a-synuclein, inherent overexpression of markers of oxidative stress, and sensitivity to peroxide-induced oxidative stress, precisely recapitulating the cause of disease in the patients [6…”
Backgroundvan der Putten, H., & Lotz, G. P. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0186-5 · Cited by 20
“[126], nuclear aberrations (PD LRRK2) [127], cell morphological changes and defects in autophagic clearance (PD) [128], and increased α-synuclein production in iPSC-derived midbrain dopaminergic neurons generated from a PD patient with a SNCA triplication [129], and a Gaucher patient with a GBA mutation that predispos…”
BackgroundAdvances in stem-cell–generated transplantation therapy for Parkinson's disease
Sundberg, M., & Isacson, O. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.876986 · Cited by 18
Saleeb, R. S., Leighton, C., Lee, J., O’Shaughnessy, J., Jeacock, K., Chappard, A., Cumberland, R., Zhao, T., Ball, S. R., Sunde, M., et al. (2023) · Science Advances · doi:10.1126/sciadv.adi7359 · Cited by 20
Self-citationComini, G., Kelly, R. L., Jarrin, S., Patton, T., Narasimhan, K., Pandit, A. S., Drummond, N. J., Kunath, T., & Dowd, E. (2024) · Journal of Neural Engineering · doi:10.1088/1741-2552/ad33b2 · Cited by 20
Self-citationAstrocytic RNA editing regulates the host immune response to alpha-synuclein
D’Sa, K., Choi, M. L., Wagen, A. Z., Setó‐Salvia, N., Kopach, O., Evans, J. R., Rodrigues, M., Lopez-Garcia, P., Lachica, J., Clarke, B. E., et al. (2025) · Science Advances · doi:10.1126/sciadv.adp8504 · Cited by 20
“S3 ). hiPSc culture hiPSCs were derived from donors who had given signed informed consent as part of the EU IMI–funded program StemBANCC and reprogrammed as described ( 77 ).”
Self-citationImportance of being Nernst: Synaptic activity and functional relevance in stem cell-derived neurons
Bradford, A. B., & McNutt, P. M. (2015) · World Journal of Stem Cells · doi:10.4252/wjsc.v7.i6.899 · Cited by 20
Lopes, C., & Rego, A. C. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9714-8 · Cited by 18
The translational potential of human induced pluripotent stem cells for clinical neurology
Devine, H. E., & Patani, R. (2016) · Cell Biology and Toxicology · doi:10.1007/s10565-016-9372-7 · Cited by 19
Baden, P., Yu, C., & Deleidi, M. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.01.023 · Cited by 17
Jacobs, B. M. (2014) · Journal of Parkinson s Disease · doi:10.3233/jpd-130268 · Cited by 20
“By generating multiple lines from each patient and only comparing lines that differentiate with similar efficiency, this variability can be controlled [14].”
BackgroundInfluentialWatmuff, B., Hartley, B. J., Hunt, C. P. J., Fabb, S. A., Pouton, C. W., & Haynes, J. M. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00104 · Cited by 20
Stem cell‐derived astrocytes: are they physiologically credible?
Hill, E. J., Nagel, D. A., Parri, H. R., & Coleman, M. D. (2016) · The Journal of Physiology · doi:10.1113/jp270658 · Cited by 20
“…disease (Zhang et al. 2010), familial dysautonomia (Lee et al. 2009), spinal muscular atrophy (Ebert et al. 2009), Rett syndrome (Marchetto et al. 2010), schizophrenia (Brennand et al. 2011), Alzheimer’s disease (Israel et al. 2012; Kondo et al. 2013) and Parkinsons’s disease (Devine et al. 2011).”
BackgroundZygogianni, O., Antoniou, N., Kalomoiri, M., Kouroupi, G., Taoufik, E., & Matsas, R. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02781-w · Cited by 18
Evolution of iPSC disease models
Zhang, W., Ding, Z., & Liu, G. (2012) · Protein & Cell · doi:10.1007/s13238-012-2005-x · Cited by 16
“In the year of 2011, a number of iPSC disease models have been successfully developed for studying the mechanism of human diseases as well as establishing platforms for drug screening and testing (Batista et al., 2011; Brennand et al., 2011; Devine et al., 2011; Itzhaki et al., 2011; Koch et al., 2011; Liu et al., 201…”
BackgroundMutant α-synuclein causes death of human cortical neurons via ERK1/2 and JNK activation
Suzuki, H., Egawa, N., Imamura, K., Kondo, T., Enami, T., Tsukita, K., Suga, M., Yada, Y., Shibukawa, R., Takahashi, R., et al. (2024) · Molecular Brain · doi:10.1186/s13041-024-01086-6 · Cited by 17
Solving the puzzle of Parkinson’s disease using induced pluripotent stem cells
Zhao, P., Luo, Z., Tian, W., Yang, J., Ibañez, D. P., Huang, Z., Tortorella, M. D., Esteban, M. A., & Fan, W. (2014) · Experimental Biology and Medicine · doi:10.1177/1535370214538588 · Cited by 21
Disease modelling using induced pluripotent stem cells: Status and prospects
Pomp, O., & Colman, A. (2012) · BioEssays · doi:10.1002/bies.201200088 · Cited by 18
Preparation of α-Synuclein Amyloid Assemblies for Toxicity Experiments
Chen, S. W., & Cremades, N. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7816-8_4 · Cited by 16
Replicates in stem cell models—How complicated!
Chan, J.-W., & Teo, A. (2020) · Stem Cells · doi:10.1002/stem.3237 · Cited by 17
Grekhnev, D. A., Kaznacheyeva, E. V., & Vigont, V. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020624 · Cited by 18
Wong, C., Chen, Y., Chien, C. L., Yu, T.-Y., Rwei, S., & Hsu, S. (2017) · Materials Science and Engineering C · doi:10.1016/j.msec.2017.08.050 · Cited by 17
“Because of the capacity for unlimited self-renewing and avoidance of ethical/legal issues, iPSCs become the most attractive cell source for regenerative medicine, disease modeling, phenotypic drug screening and in vitro pathophysiology studies [2], as well as for the therapy of various degenerative diseases such as Pa…”
BackgroundYousefi, N., Abdollahii, S., Kouhbanani, M. A. J., & Hassanzadeh, A. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29800 · Cited by 17
Research models to study lewy body dementia
Boschen, S. L., Mukerjee, A. A., Faroqi, A. H., Rabichow, B. E., & Fryer, J. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00837-w · Cited by 16
“Accumulation and aggregation of αsyn have been observed in iPSC-derived neurons from patients carrying mutations, duplications, or triplications in the SNCA gene [96, 115].”
Bhargava, A., Sandoval-Castellanos, A. M., Shah, S. S., & Ning, K. (2022) · Interface Focus · doi:10.1098/rsfs.2022.0040 · Cited by 15
Qiu, Z., Farnsworth, S. L., Mishra, & Hornsby, P. J. (2013) · Stem Cells and Cloning Advances and Applications · doi:10.2147/sccaa.s34798 · Cited by 17
“Subsequently iPS cells were formed from patients with mutations in PINK1(88) and from patients with a triplication of the SNCA gene, encoding α-synuclein.(89) Significantly, in neurons derived from iPS cells from patients with mutations in LRRK2, various differences from control cells were observed, including an incre…”
Crook, J. M., Wallace, G. G., & Tomaskovic‐Crook, E. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1013096 · Cited by 18
Recent Advances in Therapeutic Applications of Induced Pluripotent Stem Cells
Rami, F., Naderi, S., Mojaver, M., Rahimmanesh, I., Salehi, A. R., & Salehi, R. (2017) · Cellular Reprogramming · doi:10.1089/cell.2016.0034 · Cited by 16
“Lack of knowledge about these diseases is mainly due to lack of human models (Devine et al., 2011; Imaizumi and Okano, 2014).”
InfluentialCurrent Development of iPSC-Based Modeling in Neurodegenerative Diseases
Guo, X., Wang, X., Wang, J., Ma, M., & Ren, Q. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083774 · Cited by 17
“…shown that DA neurons derived from patients with SNCA triplications or gene multiplication exhibit elevated α -synuclein protein levels, increased sensitivity to oxidative and endoplasmic reticulum (ER) stress, mitochondrial dysfunction, synaptic loss, and increased neuronal death [163–169].”
Future Viable Models of Psychiatry Drug Discovery in Pharma
Rizzo, S. J. S., Edgerton, J. R., Hughes, Z. A., & Brandon, N. J. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113475871 · Cited by 14
Central nervous system organoids for modeling neurodegenerative diseases
Hou, P., & Kuo, H. (2022) · IUBMB Life · doi:10.1002/iub.2595 · Cited by 14
Kim, J. J., Daadi, E. W., Oh, T. T., Daadi, E. S., & Daadi, M. M. (2022) · Genes · doi:10.3390/genes13111937 · Cited by 14
Experimental Cell Models for Investigating Neurodegenerative Diseases
Evangelisti, C., Ramadan, S., Orlacchio, A., & Panza, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179747 · Cited by 18
“The PD line exhibited several disease phenotypes, including accumulation of α -synuclein, overexpression of oxidative stress markers, and sensitivity to peroxide-induced oxidative stress [48,49].”
BackgroundRobles-Garcia, M., Thimonier, C., Angoura, K., Ozga, E., MacPherson, H., & Blin, G. (2024) · Development · doi:10.1242/dev.202983 · Cited by 17
In vitro models of multiple system atrophy from primary cells to induced pluripotent stem cells
Abati, E., Fonzo, A. D., & Corti, S. P. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13563 · Cited by 17
Differentiation of Human Embryonic Stem Cells into Neuron, Cholinergic, and Glial Cells
Hosseini, K., Lekholm, E., Ahemaiti, A., & Fredriksson, R. (2020) · Stem Cells International · doi:10.1155/2020/8827874 · Cited by 14
“Their use is also appreciated in the field of neurodegenerative diseases [3] such as Alzheimer disease [4] and Parkinson disease [5], as well as mental disorders (Brennand, et al.”
Background
Metadata
- Authors
- Devine, M. J., Ryten, M., Vodicka, P., Thomson, A. J., Burdon, T., Houlden, H., Cavaleri, F., Nagano, M., Drummond, N. J., Taanman, J.-W., Schapira, A. H., Gwinn, K., Hardy, J., Lewis, P. A., & Kunath, T.
- Affiliations
- MRC Centre for Regenerative Medicine (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- Roslin Institute (GB)
- University of Tsukuba (JP)
- Baylor College of Medicine (US)
- Corresponding author
- Devine, Michael J.
- Kunath, Tilo
- ORCID
- Venue
- Nature Communications
- Published
- 2011-08-23
- Volume
- 2
- Issue
- 1
- Pages
- 440-440
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3265381
- OpenAlex
- W1985010554
- Cited by
- 486
- References
- 61
- Citations by year
- 2026: 12 · 2025: 25 · 2024: 27 · 2023: 25 · 2022: 40 · 2021: 26 · 2020: 43 · 2019: 24 · 2018: 46 · 2017: 34 · 2016: 34 · 2015: 38 · 2014: 29 · 2013: 32 · 2012: 48
- FWCI
- 22.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature Communications (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- ASEP (submittedVersion, public-domain)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Michael J. Fox Foundation for Parkinson's Research
- University of Dundee
- Wellcome Trust (089698)
- Parkinson's UK (K-0911, G-4046, G-0907, F1002), F-0902)
- Brain Research Trust
- University of Sheffield
- Medical Research Council (MC_G1000735)
- Biotechnology and Biological Sciences Research Council (BBS/E/R/00001627, BBS/E/R/00001601)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, induced pluripotent stem cells, alpha-synuclein, SNCA triplication, familial Parkinson's disease, midbrain dopaminergic neurons, disease modeling, neurodegeneration, multiple system atrophy, dementia with Lewy bodies, alpha-synuclein overexpression
- MeSH terms
- Cell Differentiation, Cells, Cultured, Humans, Neurons, Parkinson Disease, Gene Dosage, alpha-Synuclein, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.